In September 2023, a paper from Sweden was published in the Journal of Neurology Neurosurgery and Psychiatry (JNNP) (Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study |
Continue reading
This is about a B-cell inhibitor called Frexalimab. It is still in the pipeline and is being tested against MS. When it comes to new therapeutic strategies for the treatment of multiple sclerosis, the influence
Continue reading
“An autoimmune disease rarely comes alone” – this is a saying from medical school that certainly has its validity. Since MS is an autoimmune disease, it is not surprising that one can observe a cluster
Continue reading
Ocrelizumab (Ocrevus®) is a monoclonal antibody and belongs to the group of so-called B-cell-depleting therapies, which currently play a very important role in the immunotherapy of Multiple Sclerosis. They are used quite frequently. This article
Continue reading
This is about neural stem cells in progressive MS. Be careful, there is a risk of confusion: I had already taken a stance on stem cell therapy in the DocBlog (see DocBlog from 25.10.2019) –
Continue reading
What to do when immunoglobulin levels are lowered by B-cell depletion? – In the first post on this topic, I outlined how important B-cell-depleting therapies are for the treatment and stabilization of especially (highly) active
Continue reading B-cell depleting therapies such as Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta) or the newly approved Inebilizumab (Uplizna) for the treatment of NMOSD are currently very important tools for controlling active MS courses and for preventing relapses in
Continue reading
Finally back in person! After the meeting of the European Committee for Therapy and Research in Multiple Sclerosis (ECTRIMS) was held virtually due to the pandemic over the last two years, MS experts from all
Continue reading While there have been frequent updates about long-term immunotherapy for MS recently, the approach to treating MS relapses has remained unchanged for years. The treatment of acute MS relapses typically involves a high-dose corticosteroid preparation
Continue reading Interferons are the “original substances” for the treatment of Multiple Sclerosis. In 1993, Interferon-beta 1b (Betaferon®) from Schering (now part of the Bayer Group) was the first modern immunotherapy to be approved for MS. This
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
